CHANGE IN RATINGS
upgraded at Pipier Jaffray to Buy from Neutral based on strong customer satisfaction in recent survey. Expect market share gains and continued ecommerce innovations such as the Kindle. Price target raised to $81 from $55.
downgraded at Goldman Sachs to Sell from Neutral based on limited excess reserves and recent outperformance vs. ITU. See limited upside as investors focus on book value metrics. Price target cut to $8.50 from $9.80.
( DNA) upgraded at William Blair from Market Perform to Outperform. Company will emerge from the recession in a much stronger position.
( DNA) target cut Morgan Stanley to $97. Expect Roche deal to happen, but at a higher price. Overweight rating.
( DNA) downgraded at Jefferies from Buy to Hold. $93 price target. Expect Roche's latest offer to be successful.
( GENZ) upgraded at Deutsche Bank from Hold to Buy. $63 price target. Stock offers growth at a reasonable price.
Int'l. Game Technologies
downgraded at Goldman to Neutral from Buy based on mediocre showing in slot managers survey that indicates company is losing market share to WMS. Believe turnaround will take time and note refinancing risk. Price target cut to $9 from $14.
upgraded at Oppenheimer to Outperform. $20 price target. Valuation call, as the company will benefit from long-term demand growth.
upgraded at Credit Suisse to Outperform from Neutral based on valuation and fundamental strength of local operations in key markets outside the U.S. Raised target price to $48 from $47.
upgraded at Credit Suisse from Neutral to Outperform. $48 price target. Valuation call, as the company continues to grow outside of the U.S.
downgraded at J.P. Morgan to Neutral from Outperform based on lack of near-term positive catalysts following recent strength in shares (up 40% in 3 months). Expect no quantification of pre-salt resources in near-term.
STOCK COMMENTS / EPS CHANGES
target reduced at UBS to $36. Booking trends are likely down, and the company could be hurt by the strong dollar. Neutral rating.
target lowered at Bank of America/Merrill Lynch to $7.50. Company will be hurt by negative global GDP, but there is no change to estimates. Buy rating.
2009 numbers raised at UBS because of large booking. Company talked up competitive advantage at its Investor Day. Buy rating and new $20 price target.
2009 numbers cut at Barclays because of legacy asset marks and subdued core earnings. Equal-weight rating and new $100 price target.
estimates raised at Morgan Stanley through 2011. Company is executing well, and the balance sheet looks much better. Underweight rating and $16 price target.
numbers cut at Bank of America/Merrill Lynch to $11. Estimates also lowered, to reflect SIV expenses and continued market losses. Neutral rating.
numbers reduced at Barclays to $30. Estimates also cut, as the company likely had a loss in the first quarter, hurt by asset marks and investment losses. Equal-weight rating.
added to U.S. Focus List at Credit Suisse. $60 price target. Company will be able to take market share from weaker competitors. Outperform rating.
This article was written by a staff member of TheStreet.com.